Novel therapeutic approaches for inclusion body myositis

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of Review: This review will highlight recent advances in developing strategies to accelerate muscle regeneration and to slow muscle degeneration in myositis, focusing primarily on inclusion body myositis (IBM). Recent Findings: Therapies for accelerating muscle regeneration, primarily through inhibition of myostatin, have shown promise in the laboratory and are now entering clinical trials. Recent studies have implicated autophagy, a key cellular process involved in clearance of ubiquitinated aggregates, in the pathogenesis of familial and sporadic inclusion body myositis (sIBM). IBM has joined a growing list of diseases known as TDP-43 proteinopathies, in which this protein becomes mislocalized to the cytoplasm; however, it is unclear whether these protein aggregates or others are pathogenic in this disease. Summary: New discoveries of biomarkers in sIBM and new insights into the pathogenesis of familial IBM are opening novel therapeutic pathways for these disorders. In particular, drugs that stimulate autophagy, already in development for cancer and neurodegenerative diseases, are candidates for clinical trials. These disease-specific therapies combined with novel therapies to accelerate muscle regeneration hold promise for future therapy for this devastating disease.

Original languageEnglish (US)
Pages (from-to)658-664
Number of pages7
JournalCurrent opinion in rheumatology
Volume22
Issue number6
DOIs
StatePublished - Nov 2010

Keywords

  • TDP-43
  • autophagy
  • follistatin
  • inclusion body myositis
  • myostatin
  • regeneration
  • valosin-containing protein

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Novel therapeutic approaches for inclusion body myositis'. Together they form a unique fingerprint.

Cite this